Results 251 to 260 of about 63,636 (348)

Femoral vein Doppler ultrasound for assessing venous congestion and right heart function: a scoping review. [PDF]

Intensive Care Med Exp
Melo RH, Wong A, Koratala A, Kattan E, da Hora Passos R.   +4 more
europepmc   +1 more source

Nonalcoholic Fatty Liver Disease Status and Its Associated Factors Among Patients With Type 2 Diabetes Mellitus in Adama Hospital Medical College, South Eastern Ethiopia: A Cross‐Sectional Study

Health Science Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background and Aims Nonalcoholic fatty liver disease (NAFLD) is a condition of fat accumulation in hepatocytes, not because of excess alcohol intake and disease‐causing etiology. The disease occurrence is increased among patients with type 2 diabetes mellitus (T2DM) because of a strong pathophysiological link.
Mahider Shimelis Feyisa, Sintayehu Ambachew, Alemie Fentie Mebratie, Bruktawit Eshetu Ali, Rishan Hadgu Asefa, Elias Chane Asefa, Mahder Girma Asmamaw, Getnet Fetene   +7 more
wiley   +1 more source

Point-of-Care Ultrasonography in Advanced Nephrology Nursing Practice: Seeing Beyond the Numbers. [PDF]

Diagnostics (Basel)
Garcia-Lahosa A, Moreno-Millán S, Sanchez-García MC, Sanchez-Cardenas M, Steiss C, Escobar WJ, Nuñez-Moral M, Soler-Majoral J, Graterol Torres F, Ara J, Bover J, Sánchez-Alvarez JE, Husain-Syed F, Koratala A, Romero-González G, Fernández-Delgado S, Rodríguez-Chitiva N, Marcos-Ballesteros E.   +17 more
europepmc   +1 more source

Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

MedComm, Volume 7, Issue 2, February 2026.
VMP1 promotes angiogenesis in glioblastoma (GBM) through VEGFA‐VEGFR2 signaling and activation of endothelial cells. The FDA‐approved anti‐VEGFA antibody, bevacizumab (BEV), can counteract VMP1's tumor‐promoting effect in GBM. Targeting VMP1 or its associated pathways could be a new therapeutic strategy, either alone or in combination with BEV.
Lei Jin, Bo Chen, Junbo Liao, Wenlong Guo, Zhiyuan Zhu, Salida Ali, Gilberto Ka‐Kit Leung, Peng Wang, Karrie M. Kiang   +8 more
wiley   +1 more source

Temporary Portocaval Shunts During Liver Transplantation: A Narrative Review of Technical Solutions and Post-Transplant Outcomes. [PDF]

J Clin Med
Schirra E, Mauro A, Bianco G, Pascale MM, Frongillo F, Nure E, Avolio AW, Agnes S, Spoletini G.   +8 more
europepmc   +1 more source

Is Portal Venous Pressure or Porto-systemic Gradient Really A Harbinger of Poor Outcomes After Living Donor Liver Transplantation? [PDF]

J Clin Exp Hepatol, 2017
Kanetkar AV, Balakrishnan D, Sudhindran S, Dhar P, Gopalakrishnan U, Menon R, Sudheer OV.   +6 more
europepmc   +1 more source

Intestinal and multiple organ transplantation [PDF]

, 2000
Abu-Elmagd, K, Bueno, J, Mazariegos, G, Reyes, J, Selby, R, Starzl, TE, Todo, S   +6 more
core  

Alcohol Use After TIPS Implantation Significantly Increases the Risk of ACLF and Liver‐Related Death

United European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Complications related to portal hypertension (PH) in patients with alcohol‐related liver disease (ALD) can be controlled by transjugular intrahepatic portosystemic shunt (TIPS) placement; however, the impact of ongoing alcohol use (AU) after TIPS remains scarcely investigated.
Caroline Schwarz, Andrea Kornfehl, Reema Abid, Theresa Müllner‐Bucsics, Julia Kappel, Michael Schwarz, Benedikt S. Hofer, Nina Dominik, Georg Kramer, Benedikt Simbrunner, Mathias Jachs, Lukas Reider, Michael Trauner, Mattias Mandorfer, Thomas Reiberger, Lukas Hartl   +15 more
wiley   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 4, Page 494-506, February 2026.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas, Rachel Smith, Ellina Lytvyak, Miki Scaravaglio, Neil Halliday, Amal Almahroos, Nadia Eden, Diane Lloyd‐Madden, Sanchit Sharma, James Ferguson, Jessica K. Dyson, Douglas Thorburn, David Jones, Aldo J. Montano‐Loza, Marco Carbone, Pietro Invernizzi, George Mells, Emma L. Culver, Palak J. Trivedi   +18 more
wiley   +1 more source

Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report. [PDF]

Front Med (Lausanne)
Yang P, Zhang F, Wang F, He Y, Wang Y, Qian L.   +5 more
europepmc   +1 more source